Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide + ADT in Indian Patients With High-risk nmCRPC
NCT05348876Phase 4Recruiting
- Sponsor
- Bayer
- Start
- Aug 2022
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Aug 2022; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05348876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348876.